Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.

Koofhethile CK, Ndhlovu ZM, Thobakgale-Tshabalala C, Prado JG, Ismail N, Mncube Z, Mkhize L, van der Stok M, Yende N, Walker BD, Goulder PJR, Ndung'u T.

J Virol. 2016 Jul 11;90(15):6818-6831. doi: 10.1128/JVI.00276-16. Print 2016 Aug 1.

2.

High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection.

Gounder K, Padayachi N, Mann JK, Radebe M, Mokgoro M, van der Stok M, Mkhize L, Mncube Z, Jaggernath M, Reddy T, Walker BD, Ndung'u T.

PLoS One. 2015 Mar 17;10(3):e0119886. doi: 10.1371/journal.pone.0119886. eCollection 2015.

3.

Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection.

Radebe M, Gounder K, Mokgoro M, Ndhlovu ZM, Mncube Z, Mkhize L, van der Stok M, Jaggernath M, Walker BD, Ndung'u T.

AIDS. 2015 Jan 2;29(1):23-33. doi: 10.1097/QAD.0000000000000508.

4.

Project Masihambisane: a cluster randomised controlled trial with peer mentors to improve outcomes for pregnant mothers living with HIV.

Rotheram-Borus MJ, Richter L, Van Rooyen H, van Heerden A, Tomlinson M, Stein A, Rochat T, de Kadt J, Mtungwa N, Mkhize L, Ndlovu L, Ntombela L, Comulada WS, Desmond KA, Greco E.

Trials. 2011 Jan 4;12:2. doi: 10.1186/1745-6215-12-2.

Supplemental Content

Loading ...
Support Center